Evolocumab (anti-PCSK9)

Synonyms: AMG 145

Catalog No.A2043 Purity:99%

Evolocumab (anti-PCSK9) is a human monoclonal antibody that inhibits PCSK9. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR. Evolocumab can be used for the research of hypercholesterolemia and atherosclerotic cardiovascular diseases.

Selleck's Evolocumab (anti-PCSK9) has been cited by 1 publication

Purity & Quality Control

Batch: Purity: 99% Protein concentration: 6.47mg/ml Endotoxin Level: <1 EU/mg

Choose Selective PCSK9 Inhibitors

Name	Citation	PCSK9
PF-06446846	0	+++
PF-06446846 hydrochloride	✔
SBC-110736	✔
R-IMPP	✔
SBC-115076	✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Evolocumab (anti-PCSK9) is a human monoclonal antibody that inhibits PCSK9. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR. Evolocumab can be used for the research of hypercholesterolemia and atherosclerotic cardiovascular diseases.

References
[1] Fala L. Am Health Drug Benefits. 2016 Mar;9(Spec Feature):136-9.

References

[1] Fala L. Am Health Drug Benefits. 2016 Mar;9(Spec Feature):136-9.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1256937-27-5
Molecular Weight	141.8 KD
Isotype	Human IgG2
Application	Evolocumab (anti-PCSK9)
Sterility	0.2 μM filtered
Formulation	PBS Buffer, PH 7.4
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.